VANSEN PHARMA INC.: 10-Q filed 2013-12-04
What VANSEN PHARMA INC. reported in its quarterly report filed 2013-12-04 (fiscal Q3 2013): 26 published measures, 59 facts as tagged in accession 0001477932-13-005936.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-12-04
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001477932-13-005936 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All VANSEN PHARMA INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 7,162,194 | USD | |
| At 2012-12-31 | 15,015 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 5,182,739 | USD | |
| At 2012-12-31 | 119,478 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 1,979,455 | USD | |
| At 2012-12-31 | -104,463 | USD |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -332,424 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -332,424 | USD | 3067 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 682,302 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 682,302 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 682,302 | USD | 3067 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 4,200,000 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 4,200,000 | USD | 3067 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -3,268,155 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -3,268,155 | USD | 3067 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 2,743,965 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -1,589,849 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -1,589,849 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -1,589,849 | USD | 3067 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,057,333 | USD | |
| At 2012-12-31 | 15,015 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 34,356 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 34,356 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 34,356 | USD | 3067 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 4,979,993 | USD | |
| At 2012-12-31 | 119,478 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 682,302 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 1,871,232 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 1,871,232 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 1,871,232 | USD | 3067 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 1,432,531 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 281,383 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 281,383 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 281,383 | USD | 3067 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 85,800,004 | shares | |
| At 2012-12-31 | 42,300,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 4,001,819 | USD | |
| At 2012-12-31 | 105,506 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -2,199 | USD | |
| At 2012-12-31 | -2,199 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 4,104,861 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -2,475,597 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -2,493,895 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -2,743,965 | USD | 3067 |
| 2012-07-01 to 2012-09-30 | -8,891 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -29,745 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 1,013,987 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 1,013,987 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 1,013,987 | USD | 3067 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 195,139 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 195,139 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 195,139 | USD | 3067 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -885,748 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -885,748 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -885,748 | USD | 3067 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 682,302 | USD | 273 |
| 2005-05-09 to 2013-09-30 | 682,302 | USD | 3067 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -38,129 | USD | 273 |
| 2005-05-09 to 2013-09-30 | -38,129 | USD | 3067 |
Inspect the source
- Entity
- VANSEN PHARMA INC. / CIK 0001378076
- Captured
- SEC response SHA-256
a4f0ed9133b6b7e9e5295515e2c8f107b3eff7e5edee25a65aab492b4189c5ca
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001378076.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))